CAH

As of 2026-09-10, CAH scores 57out of 100 on QNTM’s five-factor quantitative model, a moderate conviction reading. The score blends momentum, quality, volume, value and sentiment, then adjusts for the current macro regime. CAH trades at $236.02, within its fair-value band.

CAH scores 57 out of 100 on QNTM's five-factor model — a moderate reading — neither strongly favored nor flagged for weakness at 57. Its strongest factor is value at 94 (exceptional), where it screens cheap on the model's valuation inputs, followed by quality at 56. The weakest is volume at 36, where volume gives little confirmation. Among Healthcare stocks it ranks in roughly the top 15% of the Healthcare names the model scores.

On valuation, CAH is priced in the lower part of its recent range. The profile is lopsided — a few factors carry it while others drag, so the composite masks real disagreement underneath. The blended composite before the macro overlay was 59. Same-sector names the model rates nearby include HALO, THC, TGTX.

This is a descriptive factor read on CAH, recomputed each trading day and shown with its reasoning — not a recommendation to buy, hold or sell. The score reflects where CAH sits on the model's measures today, and can change as new data arrives.

FACTOR BREAKDOWN

VALUATION RANGE

QNTM’s descriptive fair-value band for CAH runs $221.76–$284.18. Current price $236.02 sits within its fair-value band. This is valuation context, not a price target.

OTHER HEALTHCARE NAMES

QNTM provides quantitative model outputs for informational and educational purposes only. It is not investment advice and QNTM is not a registered investment adviser. Scores are rankings, not buy/sell recommendations. Data as of 2026-09-10.